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Objectives: From the widely differing complication rates published for every heart
valve, is it possible to determine a true rate for each valve and to compare the rates
of two different valves? We investigated this question for the two most popular
bileaflet valves.
Methods: Aortic valve data were abstracted from 14 St Jude Medical (St Jude
Medical Inc, Minneapolis, Minn; 33,125 patient-y) and 11 Carbomedics (Sulzer
Carbomedics Inc, Austin, Tex; 19,141 patient-y) series, and mitral valve data were
abstracted from 11 St Jude Medical (21,553 patient-y) and 8 Carbomedics (8368
patient-y) series. Regression analysis was used to accommodate heterogeneity
among rates with the same valve model, to estimate hazard ratios and 95%
confidence intervals for the valve model effect, and to incorporate other series-level
risk factors.
Results: Most of the complication rates with both valve models exhibited significant
heterogeneity. For thromboembolism and bleeding, the relative risks for valve
model were not significantly different from unity. Valve thrombosis rates exhibited
less heterogeneity: the Carbomedics valve had a lower rate in the aortic position
(hazard ratio 0.2, 95% confidence interval 0.1-0.6) and a higher rate in the mitral
position (hazard ratio 1.9, 95% confidence interval 1.0-3.8).
Conclusions: Unlike simple weighted averages of valve complication rates, regres-
sion methods can incorporate heterogeneity related to center effects and allow for
inclusion of other risk factors. Thromboembolism and bleeding rates were not
significantly different with St Jude Medical and Carbomedics valves. Valve throm-
bosis appeared to differ between the two valves, but the absolute differences in rates
were small. Because of the variability among rates with the same valve, statistical
comparisons must be interpreted cautiously.
Most currently used mechanical heart valve prostheses havecomplication rates in the same clinical range, because thosewith extreme rates are eventually discarded. This clinicalrange is still wide, however, approximately 0.5% to 3.5% peryear for aortic valve thromboembolism, for example, and onemay ask, “What is the true rate for a particular valve? and
“Which valve has the lowest rate?” Because of the variability observed from one
study to another with the same prosthesis, a single observational study obviously
cannot give the definitive answer. A review of many published, good quality studies
may provide our best possibility of answering these questions. To illustrate, we
selected the two most successful bileaflet valves, St Jude Medical (St Jude Medical
Inc, Minneapolis, Minn) and Carbomedics (Sulzer Carbomedics Inc, Austin, Tex)
and performed comparisons of thromboembolism, valve thrombosis, and bleeding
rates in both the aortic and mitral positions.
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Material and Methods
Clinical Material
From sources identified by MEDLINE searches of the English-
language journals, we selected aortic and mitral valve series pub-
lished in the last 10 years with at least 400 patient-y of follow-up.
This amount of follow-up conforms to the minimum requirements
for Food and Drug Administration marketing approval of a new
heart valve prosthesis.1 We used only articles that claimed con-
formance to either the original2 or the current3 guidelines for
reporting and that had at least 95% completeness of follow-up, as
the guidelines require. There was some inconsistency in the re-
porting of linearized rates. Most reports considered late events
only, but it was often difficult to determine this for certain. Some
other data limitations are described in Appendix 1.
From each published series we extracted by position (aortic or
mitral) the linearized event rates, the components of the rates
(number of events and total patient-years), and some potential risk
factors that may affect the rates, including follow-up complete-
ness, mean follow-up time, and longest follow-up time. If there
was a decrease in risk with time, then series with longer follow-ups
would be at an advantage. Inclusion of mean follow-up as a
potential risk factor allowed us to consider this possibility. Patient
age and gender were also collected but often were not given
separately by valve position. Other potential risk factors abstracted
were the journal (which was converted to the journal’s impact
factor), year of publication, number of valves, whether late events
only were reported, and whether major events only were reported
(for thromboembolism and bleeding).
Statistical Methods
“Linearized” rates, which assume that the risk (hazard) is constant
with time, are used to summarize many time-related complications
of heart valve replacement. For some complications, such as tissue
valve failure, this assumption is clearly inappropriate because the
hazard for failure increases with time. For several other compli-
cations, however, including thromboembolism, valve thrombosis,
and bleeding, the assumption of a constant hazard rate is consid-
ered an acceptable approximation. The Food and Drug Adminis-
tration has formulated objective performance criteria for new heart
valve approvals that are based on linearized rates. A practical
advantage of linearized rates is that most studies provide them. If
not, the rate can be easily computed from the number of events and
the total follow-up years by simple division (Rate  100 
Events/Year) to provide events per 100 valve-y, usually given as
percent per patient-year or percent per year.
A convenient statistic for expressing the relationship between
two linearized rates, for example thromboembolism with two heart
valve models, is their ratio, called the relative risk or more spe-
cifically the hazard ratio (HR). If the two risks are equal, HR
equals 1; the further HR is from unity, the greater is the valve
model effect. The 95% confidence interval (CI) gives the range of
values that are consistent with the observed data. There is a
relationship between hypothesis testing and 95% CI estimation. If
the two rates are significantly different (P  .05), then the 95% CI
does not include 1. Conversely, if the rates are not significantly
different, the 95% CI does include 1. Because they are intrinsically
related, we tended to emphasize the estimation (95% CI) approach
instead of the hypothesis testing (P value) approach. The 95% CIs
for individual linearized rates were calculated with a method
suggested by Cox.4
Given several studies of the same valve model, one might be
tempted to compute a weighted mean linearized rate (the sum of all
events divided by the sum of all follow-up years) for each valve
model and use these weighted averages to compute 95% CIs and
to compare valve models. If the rates vary significantly among
series with the same valve, however, then directly comparing the
weighted averages will produce 95% CIs and P values that are too
small, because the extra variability among series is not accounted
for. In this case a regression approach that accommodates diversity
among series and adjusts the 95% CIs and P values appropriately
should be used. If the factors that cause this heterogeneity can be
identified, they can be adjusted for in a Poisson regression analy-
sis. If such variables cannot be identified, or if they do not
sufficiently account for the heterogeneity among series, then a
regression method that allows for heterogeneity among the rates
with each valve model can be used. We used the negative binomial
distribution, a generalization of the Poisson distribution (see Ap-
pendix 2 for details). These regression models provide an estimate
of the HR for valve model adjusted for within-model heterogeneity
and can be used to examine the simultaneous effects of other
potential risk factors.
Results
Table 1 summarizes the information extracted from reports
of aortic St Jude Medical valves,5-18 and Table 2 contains
the information for aortic Carbomedics valves.6,19-28 Figures
1 through 3 contain comparison plots of the linearized rates
separated by aortic valve model for thromboembolism,
valve thrombosis, and bleeding, respectively. Table 3 sum-
marizes the information extracted from reports of mitral St
Jude Medical valves,7,8,11-16,18,29,30 and Table 4 contains the
information for mitral Carbomedics valves.19,20,22,24-26,28,31
Figures 4 through 6 contain comparison plots of the linear-
ized rates separated by mitral valve model for thromboem-
bolism, valve thrombosis, and bleeding, respectively. Note
that in most cases the rates vary widely for each valve
model and do not appear to cluster about a central value for
either model. Although we provide weighted averages
(pooled values) at the bottoms of Tables 1 through 4, we
therefore did not use these rates directly for analyses. For
example, we did not compute 95% CIs for them, nor did we
use their ratio to compute an HR. Instead, we let the regres-
sion do this, adding in the appropriate variability.
Valve Model Comparisons
Of the 12 groups of linearized rates (3 events  2 posi-
tions  2 valve models), all displayed significant (P  .05)
heterogeneity (Table 5) except for two of the valve throm-
bosis groups. Interestingly, these latter two groups had the
fewest numbers of events. Negative binomial regression
was used for all six valve model comparisons (3 events  2
positions). Table 5 contains the summary and comparison
statistics. The HRs for the effect of the Carbomedics valve
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model and their 95% CIs from the regression models are
given. None of the HRs for thromboembolism or bleeding
were significantly different from 1 (the 95% CIs contained
the value 1). In the aortic position, the Carbomedics valve
had less valve thrombosis (HR 0.16) and the 95% CI (0.06-
0.56) excluded the value 1. In the mitral position, the
Carbomedics valve had more valve thrombosis (HR 1.94)
and the 95% CI (0.98-3.84) almost excluded the value 1.
We used three series-level variables to try to adjust for
some of the variation between valves. Levels of anticoagu-
lation could affect the results. But international normalized
ratio values were not generally available for these series,
and reviewers of an earlier draft wondered whether bleeding
rate could be a surrogate for anticoagulation intensity. This
did not turn out to be the case (Figure 7). In fact, there was
a positive (rather than inverse) relationship between bleed-
ing and both thromboembolism and valve thrombosis in
both positions; in none of the regression models was the HR
for bleeding rate less than unity, which would indicate a
protective factor. So this was not considered further.
Another potentially important series-level factor was fol-
low-up time (Figure 8). If the hazard decreases with time,
then the Carbomedics series, with shorter follow-up on
average, would be at a disadvantage. We allowed mean
follow-up to enter every regression. In none of them was it
significant (P  .10), and in some its HR was greater than
1, indicating increasing risk with longer follow-up. When
the effect went in the “correct” direction, we forced it into
the model, and it changed the results somewhat in favor of
the Carbomedics valve. These results are also included in
Table 5.
The final series-level factor considered in the regression
models was follow-up completeness (Figure 9). It seems
reasonable that more complete follow-up might result in
TABLE 1. St Jude Medical aortic valves
Series Reference Valves
Follow-up
Complete Mean Longest Total Thromboembolism Thrombosis Bleeding
(%) (y) (y) (pt-y) Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
A 5 73 100 7 10 535 5 0.9 (0.4-2.0) 12 2.3 (1.2-3.8)
B 6 149 96 4 7 608 8 1.3 (0.6-2.5) 0 0.0 (0.0-0.4) 25 4.1 (2.7-6.0)
C 7 611 98 3 10 1,605 19 1.2 (0.7-1.8) 3 0.2 (0.1-0.5) 14 0.9 (0.5-1.4)
D 8 275 97 6 13 1,640 10 0.6 (0.3-1.1) 0 0.0 (0.0-0.2) 16 1.0 (0.6-1.5)
E 9 270 100 6 16 1,654 18 1.1 (0.7-1.7) 0 0.0 (0.0-0.2) 21 1.2 (0.8-1.9)
F 10 412 100 4 10 1,800 18 1.0 (0.6-1.5) 22 1.2 (0.8-1.8)
G 11 194 96 10 15 1,843 37 2.0 (1.4-2.7) 3 0.2 (0.0-0.4)
H 12 425 98 4 12 1,852 25 1.4 (0.9-2.0) 1 0.1 (0.0-0.3) 2 0.1 (0.0-0.3)
I 13 204 100 10 10 1,969 73 3.7 (2.9-4.6) 0 0.0 (0.0-0.1) 33 1.7 (1.2-2.3)
J 14 418 97 6 16 2,376 49 2.1 (1.5-2.7) 6 0.3 (0.1-0.5) 64 2.7 (2.1-3.4)
K 15 578 100 4 13 2,441 59 2.4 (1.8-3.1) 2 0.1 (0.0-0.3) 42 1.7 (1.3-2.3)
L 16 666 97 6 20 3,881 97 2.5 (2.0-3.0) 12 0.3 (0.2-0.5) 78 2.0 (1.6-2.5)
M 17 694 100 6 18 4,502 53 1.2 (0.9-1.5) 2 0.0 (0.0-0.1) 24 0.5 (0.4-0.8)
N 18 773 95 8 15 6,419 54 0.8 (0.6-1.1) 16 0.2 (0.1-0.4) 61 1.0 (0.7-1.2)
Total 5742 33,125 525 1.58 45 0.15 414 1.32
TABLE 2. Carbomedics aortic valves
Series Reference Valves
Follow-up
Complete Mean Longest Total Thromboembolism Thrombosis Bleeding
(%) (y) (y) (pt-y) Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
O 19 209 97 2 5 522 16 3.1 (1.8-4. 9) 0 0.0 (0.0-0.5) 10 1.9 (1.0-3.4)
P 6 139 97 4 7 587 9 1.5 (0.8-2.8) 0 0.0 (0.0-0.4) 19 3.2 (2.0-5.0)
Q 20 239 99 4 8 928 22 2.4 (1.5-3.5) 0 0.0 (0.0-0.3) 14 1.5 (0.9-2.5)
R 21 361 98 3 6 937 11 1.2 (0.6-2.0) 0 0.0 (0.0-0.3) 12 1.3 (0.7-2.2)
S 22 359 98 3 6 1,248 17 1.4 (0.9-2.2) 0 0.0 (0.0-0.2) 24 1.9 (1.3-2.8)
T 23 603 98 3 5 1,560 17 1.1 (0.7-1.7) 0 0.0 (0.0-0.2) 25 1.6 (1.1-2.3)
U 24 613 98 4 9 2,378 88 3.7 (3.0-4.5) 0 0.0 (0.0-0.1) 52 2.2 (1.7-2.8)
V 25 689 99 4 7 2,495 41 1.6 (1.2-2.2) 1 0.0 (0.0-0.2) 41 1.6 (1.2-2.2)
W 26 469 98 6 9 2,580 7 0.3 (0.1-0.5) 0 0.0 (0.0-0.1) 11 0.4 (0.2-0.7)
X 27 1019 100 3 9 2,730 26 1.0 (0.6-1.4) 2 0.1 (0.0-0.2) 47 1.7 (1.3-2.3)
Y 28 771 100 4 8 3,176 1 0.0 (0.0-0.1) 22 0.7 (0.5-1.0)
Total 5471 19,141 254 1.59 4 0.02 277 1.45
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higher event rates. Thus we allowed follow-up percentage to
enter every model. It was never close to significant, and
only in three models was its HR greater than 1 (meaning
higher percentage associated with higher event rate). When
forced into these three models, it made only the slightest
change, at most 0.02 decrease in the HR for valve model.
Figure 1. Thromboembolism (TE) rates for St Jude Medical and Carbomedics aortic valves. Each circle represents
1 series, with area of circle proportional to number of patient-years in series, as shown by calibration circle in
upper left. Solid horizontal lines represent weighted average for each valve model. Horizontal dashed line (3.0%/y)
represents Food and Drug Administration’s objective performance criterion (OPC) for new valve approvals.
Figure 2. Thrombosis rates for St Jude Medical and Carbomedics aortic valves. Each circle represents 1 series,
with area of circle proportional to number of patient-years in series, as shown by calibration circle in upper left.
Solid horizontal lines represent weighted averages for each valve model. The Food and Drug Administration’s
criterion for new valve approvals (0.8%/y) is not shown on this graph.
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Discussion
Comparing complication rates between established, clini-
cally acceptable heart valves would be an ideal task for a
randomized study. However, there are major implementa-
tion difficulties with such studies. They are extremely re-
source intensive, requiring many years and many valves to
complete. The AVERT study of the St Jude Medical Silzone
valve, designed to distinguish a 50% reduction in endocar-
ditis rates, required 4400 valves and 4 years’ time to com-
plete.32 The major heart valve randomized studies have
taken so long to conduct that the valves originally entered
into the study were no longer in use when the study was
finished.33 And the results of those studies only confirmed
what was already known from published observational stud-
ies.
Thus observational studies provide almost all of the
known valve complication information. However, observa-
tional studies have an important disadvantage. When a
randomized study is begun, its existence is generally an-
nounced, and the results eventually become available. How-
ever, most reports of observational studies are ad hoc; the
decision to publish is usually made after the data are col-
lected and analyzed and the results are known. Thus the
series reported in the literature may not be representative of
Figure 3. Bleeding rates for St Jude Medical and Carbomedics aortic valves. Each circle represents 1 series, with
area of circle proportional to number of patient-years in series, as shown by calibration circle in upper left. Solid
horizontal lines represent weighted averages for each valve model. Horizontal dashed lines represent Food and
Drug Administration’s criteria for major bleeding (1.5%/y) and all bleeding (3.0%/y).
TABLE 3. St. Jude Medical mitral valves
Series Reference Valves
Follow-up
Complete Mean Longest Total Thromboembolism Thrombosis Bleeding
(%) (y) (y) (pt-y) Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
A 11 94 96 9 15 869 25 2.9 (1.9-4.2) 0 0.0 (0.0-0.3)
B 29 385 99 2 5 926 47 5.1 (3.8-6.7) 3 0.3 (0.1-0.9) 8 0.9 (0.4-1.6)
C 8 166 97 6 13 930 3 0.3 (0.1-0.9) 1 0.1 (0.0-0.5) 11 1.2 (0.6-2.0)
D 7 490 98 3 10 1,287 42 3.3 (2.4-4.4) 4 0.3 (0.1-0.7) 15 1.2 (0.7-1.9)
E 13 163 100 9 10 1,520 78 5.1 (4.1-6.4) 1 0.1 (0.0-0.3) 28 1.8 (1.3-2.6)
F 18 207 95 8 15 1,580 28 1.8 (1.2-2.5) 7 0.4 (0.2-0.9) 14 0.9 (0.5-1.4)
G 15 440 100 4 12 1,782 78 4.4 (3.5-5.5) 2 0.1 (0.0-0.4) 50 2.8 (2.1-3.7)
H 14 292 97 6 16 1,868 63 3.4 (2.6-4.3) 1 0.1 (0.0-0.3) 29 1.6 (1.1-2.2)
I 16 513 97 5 20 2,662 77 2.9 (2.3-3.6) 5 0.2 (0.1-0.4) 51 1.9 (1.4-2.5)
J 12 636 98 5 12 3,252 53 1.6 (1.2-2.1) 3 0.1 (0.0-0.2) 6 0.2 (0.1-0.4)
K 30 440 98 11 19 4,877 34 0.7 (0.5-1.0) 10 0.2 (0.1-0.4) 49 1.0 (0.8-1.3)
Total 3826 21,553 528 2.45 37 0.17 261 1.26
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the experience in general. And this publication bias may
occur preferentially when the outcomes are either favorable
or unfavorable. This phenomenon has been recently dem-
onstrated for the outcome of operative mortality after car-
diac surgery.34
We have previously compiled reviews of published valve
complication rates and used graphic techniques to compare
them visually, but we refrained from performing formal
analytical comparisons because of the great variability
among series.35,36 We therefore did not produce weighted
average rates for each model, either to characterize a par-
ticular model or to make comparisons between valve mod-
els. These comparisons were purely descriptive, not infer-
ential.
However, it is natural to pool the results across many
studies of the same valve and try to draw an overall con-
clusion regarding complication rates, and some have done
so through simple comparison of the pooled means. This
study found significant heterogeneity among 10 of the 12
subgroups of event rates (Table 5). This implies that simple
pooled (weighted average) rates cannot be compared di-
rectly. The reasons for the heterogeneity could include
patient-specific risk factors (many are known) and center-
specific factors (postoperative management and data collec-
tion methods). To this list would have been added “event
definitions”; however, all these reports claim to adhere to
the guidelines for reporting.
It has been claimed that thromboembolism is predomi-
TABLE 4. Carbomedics mitral valves
Series Reference Valves
Follow-up
Complete Mean Longest Total Thromboembolism Thrombosis Bleeding
(%) (y) (y) (pt-y) Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
L 19 189 97 2 5 431 16 3.7 (2.2-5.9) 2 0.5 (0.1-1.5) 12 2.8 (1.5-4.7)
M 22 167 98 3 6 580 12 2.1 (1.1-3.5) 2 0.3 (0.1-1.1) 9 1.6 (0.8-2.8)
N 28 169 100 4 8 677 3 0.4 (0.1-1.2) 2 0.3 (0.1-1.0)
O 20 167 99 5 8 800 6 0.8 (0.3-1.5) 0 0.0 (0.0-0.3) 7 0.9 (0.4-1.7)
P 25 328 99 3 7 1096 16 1.5 (0.9-2.3) 2 0.2 (0.0-0.6) 25 2.3 (1.5-3.3)
Q 31 428 100 3 5 1398 30 2.1 (1.5-3.0) 7 0.5 (0.2-1.0) 21 1.5 (1.0-2.3)
R 24 447 98 4 9 1571 64 4.1 (3.2-5.2) 11 0.7 (0.4-1.2) 37 2.3 (1.7-3.2)
S 26 330 98 6 9 1815 6 0.3 (0.1-0.7) 1 0.1 (0.0-0.3) 5 0.3 (0.1-0.6)
Total 2225 8368 150 1.95 28 0.33 118 1.41
Figure 4. Thromboembolism rates for St Jude Medical and Carbomedics mitral valves. Each circle represents 1
series, with area of circle proportional to number of patient-years in series, as shown by calibration circle in upper
left. Solid horizontal lines represent weighted averages for each valve model. Horizontal dashed line (3.0%/y)
represents Food and Drug Administration’s objective performance criterion for new valve approvals.
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nantly patient related, whereas thrombosis is more indica-
tive of prosthesis function.37 In this study the two valve
models had similar thromboembolism and bleeding rates in
both positions, but valve thrombosis rates were different. In
the mitral position the Carbomedics valve’s rate was higher,
as has been alluded to by some previous studies.24,38,39
There was a significantly lower valve thrombosis rate in the
aortic position with the Carbomedics valve. Because throm-
bosis rates themselves are low, however, the differences
between them (rather than the ratios) are extremely small,
Figure 5. Thrombosis rates for St Jude Medical and Carbomedics mitral valves. Each circle represents 1 series,
with area of circle proportional to number of patient-years in series, as shown by calibration circle in upper left.
Solid horizontal lines represent weighted averages for each valve model. Horizontal dashed line (0.8%/y)
represents Food and Drug Administration’s objective performance criterion for new valve approvals.
Figure 6. Bleeding rates for St Jude Medical and Carbomedics mitral valves. Each circle represents 1 series, with
area of circle proportional to number of patient-years in series, as shown by calibration circle in upper left. Solid
horizontal lines represent weighted averages for each valve model. Horizontal dashed lines represent Food and
Drug Administration’s criteria for major bleeding (1.5%/y) and all bleeding (3.0%/y).
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representing an incidence of fewer than 2 thromboses in
1000 patient-y. This may be a situation where statistical
significance, if it exists, does not imply a clinically impor-
tant difference.
The findings of this study must be viewed with caution.
We have stressed the statistical limitations of combining
and comparing diverse valve series. There are also limita-
tions related to data collection (Appendix 1) and definitions.
For example, we attempted to adjust for intensity of fol-
low-up by incorporating follow-up completeness in the
models. However, completeness of follow-up may be a poor
surrogate for follow-up intensity. There is a difference be-
tween a prospectively oriented follow-up system, in which
patients are periodically contacted from their surgical dates
forward, and a retrospective approach, where patients may
be contacted for the first time perhaps 10 years after the
TABLE 5. Pooled event rates and HRs for comparison of event rates
Event Valve
Pooled event rates Valve only in model Mean follow-up forced in
Rate (%/y) Cochran* P value HR† 95% CI HR† 95% CI
Aortic position
Thromboembolism St Jude 1.58 .001 1.06 0.68-1.66
Carbomedics 1.59 .001
Valve thrombosis St Jude 0.14 .005 0.16 0.05-0.56
Carbomedics 0.02 .777
Bleeding St Jude 1.32 .001 1.06 0.66-1.70 0.98 0.55-1.76
Carbomedics 1.45 .001
Mitral position
Thromboembolism St Jude 2.45 .001 0.72 0.38-1.38 0.54 0.27-1.09
Carbomedics 1.95 .001
Valve thrombosis St Jude 0.17 .111 1.94 0.98-3.84 1.58 0.73-3.41
Carbomedics 0.33 .03
Bleeding St Jude 1.26 .001 1.1 0.60-2.00 0.94 0.49-1.83
Carbomedics 1.41 .001
*Heterogeneity among series was tested with Cochran test.
†HR for valve model effect of Carbomedics valve.
Figure 7. Relationship of thromboembolism (TE) and valve thrombosis (VT) rates (in percent per year, on vertical
axes) to bleeding rates (in percent per year, on horizontal axes). Open circles indicate St Jude Medical series and
filled circles indicate Carbomedics series.
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operation. Thus even though a retrospective and a prospec-
tive series might have the same overall percentage of com-
pleteness, the one with a retrospective approach is much less
likely to reveal intervening events, especially nonfatal ones,
than is the one with a prospective approach. We tried to
incorporate heterogeneity among series into our analyses
Figure 9. Relationship of thromboembolism (TE) and valve thrombosis (VT) rates (in percent per year on vertical
axes) to completeness of follow-up (FU, in percent, on horizontal axes). Open circles indicate St Jude Medical
series and filled circles indicate Carbomedics series.
Figure 8. Relationship of thromboembolism (TE) and valve thrombosis (VT) rates (in percent per year, on vertical
axes) to mean follow-up (FU, in years, on horizontal axes). Open circles indicate St Jude Medical series and filled
circles indicate Carbomedics series.
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but were still unable to explain this heterogeneity. With so
many factors able to influence the results from different
centers, it is difficult to combine analyses across different
studies on the basis of published results.
Four journal referees provided thoughtful and constructive re-
views of earlier drafts of this article and were responsible for
several improvements in its scope and focus.
References
1. Division of Cardiovascular and Neurological Devices, Center for
Devices and Radiological Health, Food and Drug Administration.
Draft replacement heart valve guidance, version 4.1. 1994. http://
www.fda.gov/cdrh/ode/3751.html.
2. Edmunds LH Jr, Cohn LH, Weisel RD. Guidelines for reporting
morbidity and mortality after cardiac valvular operations. J Thorac
Cardiovasc Surg. 1988;96:351-3.
3. Edmunds LH Jr, Clark RE, Cohn LH, Grunkemeier GL, Miller DC,
Weisel RD. Guidelines for reporting morbidity and mortality after
cardiac valvular operations. J Thorac Cardiovasc Surg. 1996;112:708-
11.
4. Cox DR. Some simple approximate test for Poisson variates. Bi-
ometrika. 1953;40:354-60.
5. Myken PS, Caidahl K, Larsson P, Larsson S, Wallentin I, Berggren
HE. Mechanical versus biological valve prosthesis: a ten-year com-
parison regarding function and quality of life. Ann Thorac Surg.
1995;60(2 Suppl):S447-52.
6. Lim KH, Caputo M, Ascione R, Wild J, West R, Angelini GD, et al.
Prospective randomized comparison of CarboMedics and St Jude
Medical bileaflet mechanical heart valve prostheses: an interim report.
J Thorac Cardiovasc Surg. 2002;123:21-32.
7. Fernandez J, Laub GW, Adkins MS, Anderson WA, Chen C, Bailey
BM, et al. Early and late-phase events after valve replacement with the
St Jude Medical prosthesis in 1200 patients. J Thorac Cardiovasc
Surg. 1994;107:394-406.
8. Smith JA, Westlake GW, Mullerworth MH, Skillington PD, Tatoulis
J. Excellent long-term results of cardiac valve replacement with the St
Jude Medical valve prosthesis. Circulation. 1993;88(5 Pt 2):II49-54.
9. Sawant D, Singh AK, Feng WC, Bert AA, Rotenberg F. St Jude
Medical cardiac valves in small aortic roots: follow-up to sixteen
years. J Thorac Cardiovasc Surg. 1997;113:499-509.
10. Peterseim DS, Cen YY, Cheruvu S, Landolfo K, Bashore TM, Lowe
JE, et al. Long-term outcome after biologic versus mechanical aortic
valve replacement in 841 patients. J Thorac Cardiovasc Surg. 1999;
117:890-7.
11. Debetaz LF, Ruchat P, Hurni M, Fischer A, Stumpe F, Sadeghi H, et
al. St Jude Medical valve prosthesis: an analysis of long-term outcome
and prognostic factors. J Thorac Cardiovasc Surg. 1997;113:134-48.
12. Nakano K, Koyanagi H, Hashimoto A, Kitamura M, Endo M, Na-
gashima M, et al. Twelve years’ experience with the St Jude Medical
valve prosthesis. Ann Thorac Surg. 1994;57:697-702.
13. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected findings
concerning thromboembolic complications and anticoagulation after
complete 10 year follow up of patients with St Jude Medical prosthe-
ses. J Heart Valve Dis. 1993;2:291-301.
14. Zellner JL, Kratz JM, Crumbley AJ 3rd, Stroud MR, Bradley SM,
Sade RM, et al. Long-term experience with the St Jude Medical valve
prosthesis. Ann Thorac Surg. 1999;68:1210-8.
15. Ibrahim MO, Kane H, Cleland J, Gladstone D, Sarsam M, Patterson C.
The St Jude Medical prosthesis: a thirteen-year experience. J Thorac
Cardiovasc Surg. 1994;108:221-30.
16. Khan SS, Trento A, DeRobertis M, Kass RM, Sandhu M, Czer LS, et
al. Twenty-year comparison of tissue and mechanical valve replace-
ment. J Thorac Cardiovasc Surg. 2001;122:257-69.
17. Lund O, Nielsen SL, Arildsen H, Ilkjaer LB, Pilegaard HK. Standard
aortic St Jude valve at 18 years: performance profile and determinants
of outcome. Ann Thorac Surg. 2000;69:1459-65.
18. Baudet EM, Puel V, McBride JT, Grimaud JP, Roques F, Clerc F, et
al. Long-term results of valve replacement with the St Jude Medical
prosthesis. J Thorac Cardiovasc Surg. 1995;109:858-70.
19. Nistal JF, Hurle A, Revuelta JM, Gandarillas M. Clinical experience
with the CarboMedics valve: early results with a new bileaflet me-
chanical prosthesis. J Thorac Cardiovasc Surg. 1996;112:59-68.
20. Soga Y, Okabayashi H, Nishina T, Enomoto S, Shimada I, Miyamoto
TA, et al. Up to 8-year follow-up of valve replacement with Carbo-
medics valve. Ann Thorac Surg. 2002;73:474-9.
21. Knez I, Machler H, Rehak P, Oberwalder P, Anelli-Monti M, Dacar D,
et al. Concomitant procedures in the small versus standard aortic root.
J Heart Valve Dis. 1996;5 Suppl 3:S294-301.
22. Rodler SM, Moritz A, Schreiner W, End A, Dubsky P, Wolner E.
Five-year follow-up after heart valve replacement with the CarboMed-
ics bileaflet prosthesis. Ann Thorac Surg. 1997;63:1018-25.
23. Copeland JG 3rd. An international experience with the CarboMedics
prosthetic heart valve. J Heart Valve Dis. 1995;4:56-62.
24. Jamieson WR, Fradet GJ, Miyagishima RT, Henderson C, Brownlee
RT, Zhang J, et al. CarboMedics mechanical prosthesis: performance
at eight years. J Heart Valve Dis. 2000;9:678-87.
25. Dalrymple-Hay MJ, Pearce R, Dawkins S, Haw MP, Lamb RK,
Livesey SA, et al. A single-center experience with 1,378 CarboMedics
mechanical valve implants. Ann Thorac Surg. 2000;69:457-63.
26. Santini F, Casali G, Viscardi F, Favaro A, Luciani GB, Pentiricci S, et
al. The Carbomedics prosthetic heart valve: experience with 1,084
implants. J Heart Valve Dis. 2002;11:121-6.
27. Li HH, Hahn J, Urbanski P, Torka M, Grunkemeier GL, Hacker RW.
Intermediate-term results with 1,019 Carbomedics aortic valves. Ann
Thorac Surg. 2001;71:1181-7.
28. Fiane AE, Geiran OR, Svennevig JL. Up to eight years’ follow-up of
997 patients receiving the CarboMedics prosthetic heart valve. Ann
Thorac Surg. 1998;66:443-8.
29. Jamieson WR, Miyagishima RT, Grunkemeier GL, Germann E, Hen-
derson C, Fradet GJ, et al. Bileaflet mechanical prostheses perfor-
mance in mitral position. Eur J Cardiothorac Surg. 1999;15:786-94.
30. Remadi JP, Baron O, Roussel C, Bizouarn P, Habasch A, Despins P,
et al. Isolated mitral valve replacement with St Jude Medical prosthe-
sis: long-term results: a follow-up of 19 years. Circulation. 2001;103:
1542-5.
31. Copeland JG. The CarboMedics prosthetic heart valve in the mitral
position: results of the multicenter international trial. J Card Surg.
1997;12:205-9.
32. Schaff H, Carrel T, Steckelberg JM, Grunkemeier GL, Holubkov R.
Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a
multicenter randomized trial. J Heart Valve Dis. 1999;8:131-9.
33. Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year
comparison of a Bjork-Shiley mechanical heart valve with porcine
bioprostheses. N Engl J Med. 1991;324:573-9.
34. Anyanwu AC, Treasure T. Unrealistic expectations arising from mor-
tality data reported in the cardiothoracic journals. J Thorac Cardio-
vasc Surg. 2002;123:16-20.
35. Grunkemeier GL, Starr A. Alternatives to randomization in surgical
studies. J Heart Valve Dis. 1992;1:142-51.
36. Grunkemeier GL, Li HH, Naftel DC, Starr A, Rahimtoola SH. Long-
term performance of heart valve prostheses. Curr Probl Cardiol.
2000;25:73-154.
37. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL. Twenty
years’ experience with the Medtronic Hall valve. J Thorac Cardiovasc
Surg. 2001;121:1090-100.
38. Rosengart TK, O’Hara M, Lang SJ, Ko W, Altorki N, Krieger KH, et
al. Outcome analysis of 245 CarboMedics and St Jude valves im-
planted at the same institution. Ann Thorac Surg. 1998;66:1684-91.
39. Craver J. Carbomedics Prosthetic Heart Valve. Eur J Cardiothorac
Surg. 1999;15 Suppl 1:S3-11.
40. Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity
anticoagulation therapy results in lower complication rates with the St
Jude Medical prosthesis. J Thorac Cardiovasc Surg. 1994;107:1136-
45.
41. Emery RW, Arom KV, Nicoloff DM. Utilization of the St Jude
Medical prosthesis in the aortic position. Semin Thorac Cardiovasc
Surg. 1996;8:231-6.
Grunkemeier and Wu Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 2 299
A
CD
42. Aoyagi S, Oryoji A, Nishi Y, Tanaka K, Kosuga K, Oishi K. Long-
term results of valve replacement with the St Jude Medical valve.
J Thorac Cardiovasc Surg. 1994;108:1021-9.
43. de la Fuente A, Sanchez R, Romero J, Berjon J, Imizcoz MA,
Fernandez JL, et al. CarboMedics and Monostrut valves: clinical and
hemodynamic outcomes in a randomized study. J Heart Valve Dis.
2000;9:303-7.
44. Aagaard J, Hansen CN, Tingleff J, Rygg I. Seven-and-a-half years
clinical experience with the CarboMedics prosthetic heart valve.
J Heart Valve Dis. 1995;4:628-33.
45. Bernal JM, Rabasa JM, Gutierrez-Garcia F, Morales C, Nistal JF,
Revuelta JM. The CarboMedics valve: experience with 1,049 im-
plants. Ann Thorac Surg. 1998;65:137-43.
46. Lachin JM. Biostatistical methods. New York: John Wiley & Sons;
2000.
47. Cochran W. Some methods of strengthening the common 2 tests.
Biometrics. 1954;10:417-51.
48. Venables WN, Ripley BD. Modern applied statistics with S-PLUS.
New York: Springer-Verlag; 1997.
49. Schall R. Estimation in generalized linear models with random effects.
Biometrika. 1991;78:719-27.
Appendix 1
Data Limitations
● There is a simple relationship between the linearized rate, the
number of events, and the total follow-up years. We needed
all three for the analysis, so if one of them was not given in
the article, we derived it from the other two. If only one of the
three was given, we did not use that article. If all three were
given but were inconsistent with each other, we tried to
determine the two most reliable values and recalculated the
third.
● When total follow-up years were not given separately by
position, we calculated them from the linearized rates and
numbers of events if they were available. Otherwise we
derived them as proportions of the total follow-up years
according to the ratios of patients with each valve position.
● If thrombosis was included in the thromboembolism rate, we
recalculated that rate to exclude the valve thromboses.
● One aortic Carbomedics series23 and 1 mitral Carbomedics
series31 were multicenter studies; publications from one of
the investigators of those studies24,29 may include some over-
lap.
● One series defined late events as those occurring after 3
months40 and focused on anticoagulation management only,
so we did not use that study.
● A few series were considered in the analyses but did not meet
one of the selection criteria: 2 aortic series41,42 and 1 mitral
series42 had follow-up completeness between 92% and 94%;
2 aortic series28,43 included only major thromboembolic
events, and 1 article did not mention adherence to the guide-
lines for reporting.44
● Even though 1 Carbomedics reference45 appeared to update a
previous reference,19 it did not separate thromboembolism by
position, and the newer reference had fewer bleeding events
because of a stricter definition of major bleeding.
Appendix 2
Statistical Details
If events occur independently at a constant rate of R per patient-
year, the number of events E in Y patient-years follows a Poisson
distribution (with parameter RY); the maximum likelihood esti-
mate of R is E/Y. In the cardiac surgical literature this estimate is
multiplied by 100 to convert it to events per 100 years, or per-
centage per year, and called the linearized rate.
If the rates in several series with the same valve are assumed to
be equal, then their weighted average can be directly compared
with, for example, a likelihood ratio test or an F test, as suggested
by Cox.4 A more general way to compare valve models when the
rates among series with each model are similar is to use Poisson
regression.46 Here the series are not directly pooled, and risk
factors that differ among series can be incorporated to provide a
HR for the effect of valve model adjusted for these other factors.
Before Poisson regression is used, however, series with the
same valve model should be tested for homogeneity. A test for this
could be a likelihood ratio test or the 2 goodness-of-fit test
attributed to Cochran.47 If there is significant heterogeneity among
the rates for series with the same valve model, then Poisson
regression should not be used directly, unless the heterogeneity can
be accounted for by including other risk factors. If not, then a
modification of simple Poisson regression can be used to account
for the heterogeneity. One way is to use the negative binomial
distribution. The negative binomial distribution is used to model
count data from subgroups that have Poisson distributions but with
differing rates that themselves have a gamma distribution.48 The
negative binomial distribution is a generalization of the Poisson
distribution in the sense that the variance of the negative binomial
has an additional dispersion parameter; if this is 0, the negative
binomial collapses to the Poisson.
Another regression method is to include a random effect for
medical center in the model to accommodate unmeasured variation
that valves from the same center have in common but that may
vary among different centers.49 We used this method in several of
the analyses but did not include the results because they were
similar to those from the negative binomial regressions. The S-
PLUS 2000 statistical program (Insightful Corporation, Seattle,
Wash) was used for all analyses. The S-PLUS functions used for
Poisson, negative binomial, and random effect regressions were
glm (generalized linear models), glm.nb (generalized linear model,
negative binomial) and reglm (random effects generalized linear
model), respectively.
Surgery for Acquired Cardiovascular Disease Grunkemeier and Wu
300 The Journal of Thoracic and Cardiovascular Surgery ● February 2003
A
CD
